Related references
Note: Only part of the references are listed.A review of environmental metabolism disrupting chemicals and effect biomarkers associating disease risks: Where exposomics meets metabolomics
Jiachen Sun et al.
ENVIRONMENT INTERNATIONAL (2022)
The associations between endocrine disrupting chemicals and markers of inflammation and immune responses: A systematic review and meta-analysis
Zhiqin Liu et al.
ECOTOXICOLOGY AND ENVIRONMENTAL SAFETY (2022)
Exposure to per- and Polyfluoroalkyl Substances and Markers of Liver Injury: A Systematic Review and Meta-Analysis
Elizabeth Costello et al.
ENVIRONMENTAL HEALTH PERSPECTIVES (2022)
Immunological mechanisms and therapeutic targets of fatty liver diseases
Hua Wang et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2021)
A Scoping Review on Lipocalin-2 and Its Role in Non-Alcoholic Steatohepatitis and Hepatocellular Carcinoma
Marinela Krizanac et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans
Kalliopi Pafili et al.
MOLECULAR METABOLISM (2021)
Polychlorinated biphenyls altered gut microbiome in CAR and PXR knockout mice exhibiting toxicant-associated steatohepatitis
Banrida Wahlang et al.
TOXICOLOGY REPORTS (2021)
Nonalcoholic Fatty Liver Disease 2020: The State of the Disease
Thomas G. Cotter et al.
GASTROENTEROLOGY (2020)
A New FGF21 Analog for the Treatment of Fatty Liver Disease
Maximilian Kleinert et al.
DIABETES (2020)
Hepatic STAMP2 mediates recombinant FGF21-induced improvement of hepatic iron overload in nonalcoholic fatty liver disease
Hye Young Kim et al.
FASEB JOURNAL (2020)
Dioxin-like and non-dioxin-like PCBs differentially regulate the hepatic proteome and modify diet-induced nonalcoholic fatty liver disease severity
Jian Jin et al.
MEDICINAL CHEMISTRY RESEARCH (2020)
FGF19 and FGF21 for the Treatment of NASH-Two Sides of the Same Coin? Differential and Overlapping Effects of FGF19 and FGF21 From Mice to Human
Emma Henriksson et al.
FRONTIERS IN ENDOCRINOLOGY (2020)
FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases
Erik J. Tillman et al.
FRONTIERS IN ENDOCRINOLOGY (2020)
Endocrine Disrupting Chemicals: An Occult Mediator of Metabolic Disease
Olga Papalou et al.
FRONTIERS IN ENDOCRINOLOGY (2019)
Endocrine disrupting chemicals: Impact on human health, wildlife and the environment
Telma Encarnacao et al.
SCIENCE PROGRESS (2019)
Polychlorinated biphenyl exposures differentially regulate hepatic metabolism and pancreatic function: Implications for nonalcoholic steatohepatitis and diabetes
Hongxue Shi et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2019)
Liver Disease in a Residential Cohort With Elevated Polychlorinated Biphenyl Exposures
Heather B. Clair et al.
TOXICOLOGICAL SCIENCES (2018)
Hepatic Iron Concentration Correlates With Insulin Sensitivity in Nonalcoholic Fatty Liver Disease
Laurence Britton et al.
HEPATOLOGY COMMUNICATIONS (2018)
Metabolism disrupting chemicals and metabolic disorders
Jerrold J. Heindel et al.
REPRODUCTIVE TOXICOLOGY (2017)
Iron overload and non-alcoholic fatty liver disease
Christian Datz et al.
MINERVA ENDOCRINOLOGICA (2017)
Polychlorinated Biphenyl-Xenobiotic Nuclear Receptor Interactions Regulate Energy Metabolism, Behavior, and Inflammation in Non-alcoholic-Steatohepatitis
Banrida Wahlang et al.
TOXICOLOGICAL SCIENCES (2016)
PCB126-Induced Disruption in Gluconeogenesis and Fatty Acid Oxidation Precedes Fatty Liver in Male Rats
Gopi S. Gadupudi et al.
TOXICOLOGICAL SCIENCES (2016)
Lipocalin 2 alleviates iron toxicity by facilitating hypoferremia of inflammation and limiting catalytic iron generation
Xia Xiao et al.
BIOMETALS (2016)
Lipocalin 2 drives neutrophilic inflammation in alcoholic liver disease
Verena Wieser et al.
JOURNAL OF HEPATOLOGY (2016)
Lipocalin-2 mediates non-alcoholic steatohepatitis by promoting neutrophil-macrophage crosstalk via the induction of CXCR2
Dewei Ye et al.
JOURNAL OF HEPATOLOGY (2016)
FGF21 ameliorates nonalcoholic fatty liver disease by inducing autophagy
Shenglong Zhu et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2016)
Iron and non-alcoholic fatty liver disease
Laurence J. Britton et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
Lipocalin 2 (LCN2) Expression in Hepatic Malfunction and Therapy
Anastasia Asimakopoulou et al.
FRONTIERS IN PHYSIOLOGY (2016)
Persistent organic pollutants and non-alcoholic fatty liver disease in morbidly obese patients: a cohort study
Panu Rantakokko et al.
ENVIRONMENTAL HEALTH (2015)
New insights into disruption of iron homeostasis by environmental pollutants
Xiang Wang et al.
JOURNAL OF ENVIRONMENTAL SCIENCES (2015)
The Relationship of Serum Hemojuvelin and Hepcidin Levels with Iron Overload in Nonalcoholic Fatty Liver Disease
Journal of Gastrointestinal and Liver Diseases (2015)
Hepatic STAMP2 alleviates high fat diet-induced hepatic steatosis and insulin resistance
Hye Y. Kim et al.
JOURNAL OF HEPATOLOGY (2015)
Fibroblast growth factor 21 analogs for treating metabolic disorders
Jun Zhang et al.
FRONTIERS IN ENDOCRINOLOGY (2015)
The effects of PCB126 on intra-hepatic mechanisms associated with non alcoholic fatty liver disease
Marie-Pier Boucher et al.
JOURNAL OF DIABETES AND METABOLIC DISORDERS (2015)
Human Receptor Activation by Aroclor 1260, a Polychlorinated Biphenyl Mixture
Banrida Wahlang et al.
TOXICOLOGICAL SCIENCES (2014)
Evaluation of Aroclor 1260 exposure in a mouse model of diet-induced obesity and non-alcoholic fatty liver disease
Banrida Wahlang et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2014)
Protective effects of lipocalin-2 (LCN2) in acute liver injury suggest a novel function in liver homeostasis
Erawan Borkham-Kamphorst et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2013)
The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes
Gregory Gaich et al.
CELL METABOLISM (2013)
PCB-77 disturbs iron homeostasis through regulating hepcidin gene expression
Lei Wang et al.
GENE (2013)
Myeloperoxidase: a front-line defender against phagocytosed microorganisms
Seymour J. Klebanoff et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2013)
Iron in fatty liver and in the metabolic syndrome: A promising therapeutic target
Paola Dongiovanni et al.
JOURNAL OF HEPATOLOGY (2011)
Iron Homeostasis and the Inflammatory Response
Marianne Wessling-Resnick
ANNUAL REVIEW OF NUTRITION, VOL 30 (2010)
Lipocalin-2 Deficiency Attenuates Insulin Resistance Associated With Aging and Obesity
Ivy K. M. Law et al.
DIABETES (2010)
Persistent Organic Pollutant Exposure Leads to Insulin Resistance Syndrome
Jerome Ruzzin et al.
ENVIRONMENTAL HEALTH PERSPECTIVES (2010)
Polychlorinated Biphenyls, Lead, and Mercury Are Associated with Liver Disease in American Adults: NHANES 2003-2004
Matt Cave et al.
ENVIRONMENTAL HEALTH PERSPECTIVES (2010)
Toxicant-Associated Steatohepatitis In Vinyl Chloride Workers
Matt Cave et al.
HEPATOLOGY (2010)
Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma: A Weighty Connection
Brad Q. Starley et al.
HEPATOLOGY (2010)
Restriction of calorie and iron intake results in reduction of visceral fat and serum alanine aminotransferase and ferritin levels in patients with chronic liver disease
Motoh Iwasa et al.
HEPATOLOGY RESEARCH (2010)
Lipocalin 2 is essential for chronic kidney disease progression in mice and humans
Amandine Viau et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Increased Urinary Lipocalin-2 Reflects Matrix Metalloproteinase-9 Activity in Chronic Hepatitis C with Hepatic Fibrosis
Jin-Wook Kim et al.
TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Increased Hepatic Myeloperoxidase Activity in Obese Subjects with Nonalcoholic Steatohepatitis
Sander S. Rensen et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
Fibroblast Growth Factor 21 Reverses Hepatic Steatosis, Increases Energy Expenditure, and Improves Insulin Sensitivity in Diet-Induced Obese Mice
Jing Xu et al.
DIABETES (2009)
Pathways underlying iron accumulation in human nonalcoholic fatty liver disease
Elmar Aigner et al.
AMERICAN JOURNAL OF CLINICAL NUTRITION (2008)
Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: Evidence from a case-control study
Luca Valenti et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2007)
FGF-21 as a novel metabolic regulator
A Kharitonenkov et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Share Paper
